With its benchmark status among ophthalmologists to treat forms of macular degeneration and multi-billion-dollar annual sales, Regeneron’s Eylea (aflibercept) represents one of the most lucrative potential US opportunities for biosimilar sponsors in the middle of this decade.
A swathe of firms is working franticly to be among the first wave, following biosimilar inroads last year into the...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?